Gossamer Bio, Inc. (4GB.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Faheem Hasnain | Co-Founder, CEO, President & Chairman | 801.96k | -- | 1958 |
| Mr. Bryan Giraudo | COO & CFO | 623.84k | -- | 1975 |
| Mr. Robert P. Smith | Chief Commercial Officer | 119.64k | -- | 1970 |
| Mr. Christian Waage J.D. | Executive Vice President of Technical Operations & Administration | 513.77k | -- | 1967 |
| Mr. Jeff Boerneke | General Counsel & Secretary | -- | -- | -- |
| Ms. Jeanine Anthony | Senior Vice President of Marketing | -- | -- | -- |
| Ms. Deanna Weber | Senior Vice President of Human Resources | -- | -- | -- |
| Dr. Richard Aranda M.D. | Chief Medical Officer | 550.85k | -- | 1961 |
| Dr. Robert F. Roscigno Ph.D. | Senior Vice President of Clinical Development of Pulmonary Vascular Disease | -- | -- | 1966 |
| Ms. Caryn L. Peterson | Executive Vice President of Regulatory Affairs | -- | -- | 1959 |
Gossamer Bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 144
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Corporate Governance
Upcoming Events
May 5, 2025 at 10:59 AM UTC - May 9, 2025 at 12:00 PM UTC
Gossamer Bio, Inc. Earnings Date
Recent Events
Recent Events Information Not Available